Table 6.

Survival under specific treatments

		Exon 4 intensity				Exon 4 %				OPN-c intensity				OPN-c %
		Logrank		Wilcoxon		Logrank		Wilcoxon		Logrank		Wilcoxon		Logrank		Wilcoxon
Treatment	n	χ2	p-value	χ2	p-value	χ2	p-value	χ2	p-value	χ2	p-value	χ2	p-value	χ2	p-value	χ2	p-value
hormone no (all subgroups)	54	7.127	0.008	9.087	0.003	0.106	0.745	0.015	0.902	3.384	0.066	5.373	0.021	0.551	0.458	0.372	0.542
hormone yes (all subgroups)	65	2.631	0.105	6.981	0.008	1.970	0.160	3.267	0.071	0.480	0.489	2.218	0.136	0.130	0.719	0.140	0.708
hormone alone	18	0.591	0.442	0.226	0.635	0.069	0.793	0.071	0.790	1.303	0.254	0.961	0.327	0.050	0.823	0.184	0.668
hormone and chemo	16	2.613	0.106	3.937	0.047	0.531	0.466	1.071	0.301	0.707	0.401	1.778	0.182	0.317	0.573	0.101	0.751
hormone and radiation	10	1.833	0.176	2.709	0.100	0.837	0.360	0.987	0.320	2.049	0.152	2.485	0.115	0.075	0.784	0.011	0.915
hormone, chemo, radiation	21	0.703	0.402	0.601	0.438	1.036	0.309	1.139	0.286	0.065	0.799	0.240	0.624	0.047	0.829	0.089	0.765
chemo no (all subgroups)	30	0.833	0.361	3.472	0.062	0.403	0.526	1.123	0.289	0.067	0.795	0.465	0.495	0.003	0.955	0.049	0.825
chemo yes (all subgroups)	89	6.588	0.010	10.593	0.001	0.387	0.534	0.566	0.452	2.858	0.091	7.465	0.006	0.614	0.433	0.186	0.667
chemo (CMF)	55	5.455	0.020	9.345	0.002	1.275	0.259	1.561	0.212	1.522	0.217	4.847	0.028	0.152	0.697	0.016	0.899
chemo (AC/CMF)	34	1.289	0.256	1.608	0.205	0.420	0.517	0.317	0.574	1.300	0.254	2.740	0.098	0.507	0.477	0.456	0.500
chemo alone	13	1.865	0.172	1.268	0.260	0.107	0.743	0.245	0.620	0.322	0.570	1.356	0.244	0.099	0.753	0.126	0.722
chemo and radiation	39	4.123	0.042	8.229	0.004	0.898	0.344	0.209	0.648	2.380	0.123	3.271	0.071	0.431	0.512	0.180	0.672
radiation no (all subgroups)	47	1.964	0.161	3.638	0.057	0.009	0.927	0.067	0.796	0.005	0.946	0.497	0.481	1.310	0.252	1.819	0.178
radiation yes (all subgroups)	72	3.786	0.052	8.444	0.004	1.143	0.285	1.690	0.194	2.395	0.122	4.766	0.029	0.122	0.727	0.090	0.764

Logrank test and Wilcoxon test for the prediction of survival by the dichotomized immunohistochemical markers in the indicated subgroups of patients. Significant p-values are underlined